Active — Not RecruitingNot Applicable

Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC

Italy300 participantsStarted 2025-07-01

Plain-language summary

This study will enroll patients with metastatic colorectal cancer treated with the combination of Trifluridine/Tipiracile and Bevacizumab across 15 italian centers.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years; * ECOG PS 0-2; * Histologic diagnosis of colorectal cancer; * Treatment with fluoropyrimidine plus bevacizumab. Exclusion Criteria: * ECOG PS ≥3; * Absence of histologic diagnosis.

What they're measuring

Overall Survival

Timeframe: up to 30 months from the date of treatments' start

Progression-free survival

Timeframe: up to 30 months from the date of treatments' start

Trial details

NCT IDNCT07494578

SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-07-01

View on ClinicalTrials.gov More Colon Cancer Metastatic trials